Taysha Gene Therapies, Inc. (TSHA)
4.245
+0.24
(+5.86%)
USD |
NASDAQ |
Oct 27, 16:00
4.25
0.00 (0.00%)
After-Hours: 20:00
Taysha Gene Therapies Enterprise Value : 905.94M for Oct. 26, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 26, 2026 | 905.94M |
| October 23, 2026 | 889.67M |
| October 22, 2026 | 904.31M |
| October 21, 2026 | 941.72M |
| October 20, 2026 | 938.47M |
| October 19, 2026 | 883.17M |
| October 16, 2026 | 779.07M |
| October 15, 2026 | 814.85M |
| October 14, 2026 | 743.29M |
| October 13, 2026 | 766.06M |
| October 12, 2026 | 948.23M |
| October 09, 2026 | 1.062B |
| October 08, 2026 | 1.043B |
| October 07, 2026 | 1.043B |
| October 06, 2026 | 1.030B |
| October 05, 2026 | 1.062B |
| October 02, 2026 | 1.108B |
| October 01, 2026 | 1.143B |
| September 30, 2026 | 1.186B |
| September 29, 2026 | 1.225B |
| September 28, 2026 | 1.225B |
| September 25, 2026 | 1.121B |
| September 24, 2026 | 1.160B |
| September 23, 2026 | 1.199B |
| September 22, 2026 | 1.280B |
| Date | Value |
|---|---|
| September 21, 2026 | 1.241B |
| September 18, 2026 | 1.234B |
| September 17, 2026 | 1.280B |
| September 16, 2026 | 1.251B |
| September 15, 2026 | 1.248B |
| September 14, 2026 | 1.231B |
| September 11, 2026 | 1.234B |
| September 10, 2026 | 1.280B |
| September 09, 2026 | 1.339B |
| September 08, 2026 | 1.384B |
| September 04, 2026 | 1.423B |
| September 03, 2026 | 1.413B |
| September 02, 2026 | 1.436B |
| September 01, 2026 | 1.456B |
| August 31, 2026 | 1.452B |
| August 28, 2026 | 1.478B |
| August 27, 2026 | 1.540B |
| August 26, 2026 | 1.560B |
| August 25, 2026 | 1.618B |
| August 24, 2026 | 1.544B |
| August 21, 2026 | 1.583B |
| August 20, 2026 | 1.589B |
| August 19, 2026 | 1.693B |
| August 18, 2026 | 1.615B |
| August 17, 2026 | 1.622B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Altimmune, Inc. | 108.37M |
| Protalix Biotherapeutics, Inc. | 167.65M |
| Humacyte, Inc. | 97.42M |
| Agenus, Inc. | 527.17M |
| Amgen, Inc. | 283.68B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -46.64M |
| Total Expenses (Quarterly) | 46.64M |
| EPS Diluted (Quarterly) | -0.1264 |
| Earnings Yield | -10.19% |
| Normalized Earnings Yield | -9.830 |